Related Experiment Videos
The case for surgery in obstructive hypertrophic cardiomyopathy
Barry J Maron1, Joseph A Dearani, Steve R Ommen
1Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota 55407, USA. hcm.maron@mhif.org <hcm.maron@mhif.org>
Journal of the American College of Cardiology
|November 16, 2004
Summary
Surgical septal myectomy is the most effective treatment for hypertrophic cardiomyopathy (HCM) outflow obstruction, offering long-term survival and improved quality of life. This surgery provides a definitive solution for drug-refractory patients, unlike newer interventions.
Area of Science:
- Cardiology
- Cardiac Surgery
Background:
- Hypertrophic cardiomyopathy (HCM) can cause disabling left ventricular (LV) outflow obstruction.
- Medical management is often insufficient for severe symptoms refractory to treatment.
Purpose of the Study:
- To re-emphasize the efficacy of surgical septal myectomy for HCM with LV outflow obstruction.
- To highlight surgery as the primary treatment option for severely symptomatic, drug-refractory patients.
Main Methods:
- Review of long-term outcomes and benefits of surgical septal myectomy over four decades.
- Comparison of surgical myectomy with other interventions like alcohol septal ablation.
Main Results:
- Surgical septal myectomy normalizes LV pressures, abolishes systolic anterior motion, and resolves mitral regurgitation.
- It offers long-term survival comparable to the general population and superior to non-operated patients.
- Surgery avoids the need for post-procedural devices and potentially arrhythmogenic substrates.
Conclusions:
- Surgical septal myectomy remains the time-honored and most effective treatment for drug-refractory HCM with LV outflow obstruction.
- It significantly improves hemodynamic function, reverses heart failure complications, and enhances quality of life.
- Surgeons can adapt the procedure for heterogeneous LV outflow tract morphologies, including mitral valve anomalies.